Novo Nordisk’s oral Wegovy in China has moved a step closer to potential market entry after the country’s drug regulator accepted the application to sell the tablet version of its GLP-1 weight-loss medicine.
The acceptance of Novo Nordisk’s regulatory application in China allows it to proceed through the regulatory review process and final marketing approval.
However, this Oral Wegovy approval in China is a significant move because China is the world’s second-largest pharmaceutical market and is becoming a major battleground for obesity medicines. The global drugmakers are also racing to capture this opportunity.
Novo Nordisk’s oral Wegovy in China could also intensify competition with Eli Lilly, which has already advanced its own once-daily weight-loss pill, orforglipron, toward the Chinese market.
Novo Nordisk’s Oral Wegovy in China Offer New Treatment Options
Most major GLP-1 medicines competing in the obesity market have focused heavily on injectable treatments. GLP-1 drugs, or glucagon-like peptide-1 receptor agonists, mimic a natural hormone involved in appetite and blood sugar regulation.
An oral weight loss drug alternative could appeal to patients who prefer not to use injections.
Both Novo Nordisk and Eli Lilly believe weight-loss pills could attract people reluctant to take injectable medicines. This makes the potential presence of the Wegovy weight-loss pill in China a commercial success.
About Novo Nordisk’s Wegovy Weight Loss Pill
Novo Nordisk’s oral Wegovy medicine contains semaglutide and is supported by Novo Nordisk’s OASIS clinical development program. The program studied once-daily semaglutide tablets in adults with obesity or overweight and related health conditions.
The Wegovy weight loss pill also uses an absorption enhancer called SNAC. SNAC helps the body absorb semaglutide more effectively after the medicine is taken orally, addressing one of the major challenges associated with delivering peptide-based medicines as tablets.
Oral Wegovy Approval in China Heats Competition With Eli Lilly
The process of oral Wegovy approval in China is unfolding against an increasingly competitive backdrop. Eli Lilly has already submitted a marketing application in China for orforglipron, its once-daily oral GLP-1 medicine.
Lilly submitted its application to Chinese regulators at the end of 2025 and has indicated that the medicine could potentially launch in China as soon as 2026.
The competition in the obesity drug market extends beyond the two pharmaceutical giants. Pfizer and Chinese company Innovent Biologics are also pursuing opportunities in the country’s broader GLP-1 treatment sector.
This growing rivalry could accelerate the availability of different treatment options for weight loss while increasing pressure on manufacturers to compete on convenience, effectiveness, access, and market reach.
Chinese Obesity Drug Market Offers Major Growth Potential
Novo Nordisk’s oral Wegovy in China has a huge growth opportunity with the country’s growing obesity challenge.
China’s National Health Commission has said that the proportion of people who are overweight or obese could exceed 65% by 2030. This rising health burden is increasing interest in long-term obesity management and creating significant demand for new treatment options with medicines such as GLP-1 therapies.
Wegovy China Approval Expands Novo Nordisk’s Global Presence
Novo Nordisk has already made progress with the oral version of Wegovy outside China. The company received early approvals for the medicine in the United States and United Kingdom and launched the tablet in the U.S. in 2026.
Wegovy’s international expansion also includes other markets. Novo Nordisk has been pursuing regulatory progress for the Wegovy weight-loss pill in Australia.
The next stage for Novo Nordisk’s oral Wegovy in China is regulatory review. Chinese authorities will determine whether the regulatory application meets the requirements for final marketing authorization. The company has not confirmed how long a decision may take.
If approved, the Wegovy weight-loss pill would enter a fast-growing and highly competitive Chinese obesity drug market.
